TaylorJEvansCBlackburnD. Patient self-medication with ASA 81 mg. Can Pharm J2010;143:192–8.
3.
PignoneMAlbertsMJColwellJA. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care2010;33:1395–402.
4.
BeckerRCMeadeTWBergerPB. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest2008;133(6 suppl);776S–814S.
5.
US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med2009;150:396–404.
6.
RedbergRFBenjaminEJBittnerV. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol2009;54:1364–405.
7.
HackamDGKhanNAHemmelgarnBR. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 — therapy. Can J Cardiol2010;26:249–58.
8.
MoscaLBenjaminEJBerraK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association. Circulation2011;123:1243–62.
9.
BellADRoussinACartierR. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol2011;27(suppl A):S1–59.
10.
Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009;373:1849–60.
11.
PetoRGrayRCollinsR. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ1988;296:313–6.
12.
Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med1989;321:129–35.
13.
RidkerPMCookNRLeeIM. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med2005;352:1293–304.
14.
HanssonLZanchettiACarruthersSG. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351:1755–62.
15.
The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351:233–41.
16.
de GaetanoG; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet2001;357:89–95.
17.
BergerJSRoncaglioniMCAvanziniF. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA2006;295:306–13.
18.
D'AgostinoRBSr.VasanRSPencinaMJ. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation2008;117:743–53.
19.
GenestJMcPhersonRFrohlichJ. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult — 2009 recommendations. Can J Cardiol2009;25:567–79.
20.
Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) study. Available: www.arrive-study.com/EN/study.cfm (accessed Sept. 19, 2011).
McQuaidKRLaineL. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med2006;119:624–38.
23.
Hernández-DíazSRodríguezLAG. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med2006;4:22.
24.
LaineL. Review article: gastrointestinal bleeding with low-dose aspirin—what's the risk?Aliment Pharmacol Ther2006;24:897–908.
25.
LaiKCLamSKChuKM. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med2002;346:2033–8.
